Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „expected“
Suchtreffer
Begriffe & Kennungen
Dupixent · 4.5 · An effect of dupilumab on the PK of co-administered medicinal products is not expected. Based on the populatio
Eintrag öffnenDupixent · 4.5 · An effect of dupilumab on the PK of co-administered medicinal products is not expected. Based on the populatio
Eintrag öffnenEbglyss · 4.5 · Given that lebrikizumab is a monoclonal antibody, no pharmacokinetic interactions are expected.
Eintrag öffnenEffentora · 4.8 · Summary of the safety profile Typical opioid adverse reactions are to be expected with Effentora. Frequently,
Eintrag öffnenElfabrio · 4.5 · Pegunigalsidase alfa is a protein and is expected to be metabolically degraded through peptide hydrolysis.
Eintrag öffnenEliquis · 4.5 · 12 concentration up to 20 μM. Therefore, apixaban is not expected to alter the metabolic clearance of coadmini
Eintrag öffnenEmgality · 4.5 · No drug interaction studies were conducted. No pharmacokinetic drug interactions are expected based on the cha
Eintrag öffnenEmgality · 4.5 · No drug interaction studies were conducted. No pharmacokinetic drug interactions are expected based on the cha
Eintrag öffnenEpclusa · 4.5 · HERBAL SUPPLEMENTS St. John’s wort Interaction not studied. Epclusa is contraindicated with Expected: St. John
Eintrag öffnenEpclusa · 4.5 · HERBAL SUPPLEMENTS St. John’s wort Interaction not studied. Epclusa is contraindicated with Expected: St. John
Eintrag öffnenEpclusa · 4.5 · Oxcarbazepine Interaction not studied. Co-administration of Epclusa with Expected: oxcarbazepine is expected t
Eintrag öffnenEpclusa · 4.5 · Oxcarbazepine Interaction not studied. Co-administration of Epclusa with Expected: oxcarbazepine is expected t
Eintrag öffnenEporatio · 4.8 · Summary of the safety profile Approximately 9% of patients can be expected to experience an adverse reaction.
Eintrag öffnenErivedge · 4.5 · Clinically significant PK interactions between vismodegib and CYP450 inhibitors are not expected. Results from
Eintrag öffnenErivedge · 4.5 · Clinically significant PK interactions between vismodegib and CYP450 substrates are not expected. In vitro, CY
Eintrag öffnenErivedge · 4.5 · Clinically significant PK interactions between vismodegib and P-gp inhibitors are not expected. Results from a
Eintrag öffnenEtcamah · 4.5 · CYP3A4/5 inducers The exposure to camizestrant is expected to decrease if co-administered with moderate and st
Eintrag öffnenEvrenzo · 4.5 · Interactions are also expected with other statins. When co-administered with roxadustat, adverse reactions ass
Eintrag öffnenEvrysdi · 4.5 · No drug‑drug interactions are expected via the FMO1 and FMO3 pathway.
Eintrag öffnenEvrysdi · 4.5 · No drug‑drug interactions are expected via the FMO1 and FMO3 pathway.
Eintrag öffnen